OriGene announced that it has recently signed a definitive agreement to acquire all of the assets of the Life Sciences business of SDIX (Strategic Diagnostics, Newark DE). The combination of SDIX and OriGene expands the company’s ability to develop the most comprehensive collection of high-quality monoclonal antibodies for key applications in research and diagnostic fields. The move also complements OriGene’s unique ability to develop the UltraMAB(TM) portfolio.
The official press release can be found here.
The deal is said to be worth $16m according to BioSpace.
